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Abstract: Tuberculosis globally results in almost 2 million human deaths annually, with 1 in 4 deaths from tuberculosis being human 
immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)-related. Primarily a pathogen of the respiratory system, 
aerobic Mycobacterium tuberculosis complex (MTBC) infects the lungs via the inhalation of infected aerosol droplets generated by 
people with pulmonary disease through coughing. This review focuses on M. tuberculosis transmission, epidemiology, detection meth-
ods and technologies.
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Introduction
Mycobacterium tuberculosis was first discovered in 
1882 by Robert Koch and is one of almost 200 myco-
bacterial species which have been detected by molec-
ular techniques.1 The genus Actinobacteria (given its 
own family, the Mycobacteriaceae) includes pathogens 
known to cause serious diseases in mammals, includ-
ing tuberculosis (MTBC) and leprosy (M. leprae).1 
Mycobacteria are grouped neither as Gram-positive 
nor Gram-negative bacteria, and have a relatively 
high average G+C content of 61 to 71 mol% for all 
species, except M. leprae (57 mol%).2,3 The genome 
size varies from species to species ranging from 4 to 
7 million base pairs (bp).2,3 90% of the genome repre-
sents coding regions that potentially encode . 6,000 
proteins.2,3 MTBC consists of M. tuberculosis, 
M. bovis, M. bovis BCG  (bacillus Calmette-Guérin), 
M. africanum M. caprae, M. microti, M. canettii and 
M. pinnipedii, all of which share genetic homology, 
with no significant variation between sequences 
(∼0.01 to 0.03%), although differences in phenotypes 
are present.4 Some species such as M. smegmatis and 
M. tuberculosis are able to grow in a limited oxygen 
environment. Cells in the genus have a typical rod, 
or slightly curved-shape, with dimensions of 0.2 to 
0.6 µm by 1 to 10 µm.1
Mycobacterium tuberculosis has a waxy mycolic 
acid lipid complex coating on its cell surface, making 
the cells impervious to Gram staining (Fig. 1). Thus, 
a common staining procedure used is Ziehl-Neelsen 
(ZN) staining.1 The outer compartment of the cell wall 
contains lipid-linked polysaccharides consisting of 
lipoarabinomannan (LAM), lipomannan, phthiocerol 
dimycocerosate, trehasole, and phosphatidylinosi-
tol mannoside, with sulfolipid only being present in 
M. tuberculosis (Fig. 1).5,6 The outer compartment of 
the cell wall is soluble and has a role in interacting 
with the host immune system. The insoluble inner 
compartment of the cell wall consists of peptidogly-
can (PG), arabinogalactan (AG), and mycolic acid 
(MA). Mycobacteria have some unique qualities that 
are divergent from members of the Gram-positive 
group, such as the presence of mycolic acids in the 
cell wall.5,7
Transmission
MTBC and M. leprae replication occurs in the tis-
sues of warm-blooded human hosts. This air-borne 
pathogen is transmitted from an active pulmonary 
tuberculosis patient by coughing.7,8 Droplet nuclei, 
approximately 1 to 5 µm in size “meander” in the 
air and are transmitted to susceptible individuals by 
inhalation. Mycobacteria are incapable of  replicating 
in or on inanimate objects. The risk of infection is 
dependent to the load of the bacillus that has been 
inhaled, level of infectiousness, person-to- person 
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Figure 1. Schematic representation of Mycobacterium, showing the main components of the outer and inner layer of the cell wall.
notes: The presence of mycolic acid in the complex of covalent-linked MA-AG-PG is a unique character for identification of the genus Mycobacterium and 
plays an important role as a permeability barrier. Reproduced with permission from elsevier.76
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contact perimeter and the immune competency of 
potential hosts. Due to the size of the droplets inhaled 
into the lungs, the infection penetrates the defense 
systems of the bronchi and enters the terminal alve-
oli. Invading bacteria are then engulfed by alveolar 
macrophage and dendritic cells.7–9 The cell- mediated 
immune response alleviates the multiplication of 
M. tuberculosis and halts infection.  Tuberculosis 
can also infect other vital organs of the human body 
such as the kidneys, spine and brain. Infected indi-
viduals with strong immune systems are generally 
able to combat the infection within 2 to 8 weeks 
post-infection, when the active cell-mediated immune 
response stops further multiplication of M. tubercu-
losis. With latent tuberculosis, the tubercle (infected 
macrophage or granuloma) bacilli are not completely 
eradicated from immune system, appearing asymp-
tomatic for a longer period of time.7–9 Although 
tuberculosis is curable, available treatment regimens 
merely slow the infection rate rather than  eliminating 
the infection from the population. However, the use 
of first-line drugs to treat M. tuberculosis does have 
an effect within 6 months in susceptible patients. 
For the unsusceptible patient, second-line drug treat-
ments are introduced that are used to treat the mul-
tidrug-resistant tuberculosis (MDR-TB).8 Latently 
infected  individuals are non-infectious, and the 
infection can be detected by tuberculin skin tests 
(TST) and interferon gamma release assays (IGRA).8 
While latent tuberculosis has a low potential to cause 
recurrent infection (approximately 10%), it has 
been reported that reactivation of latent tuberculosis 
(active tuberculosis) may occur after years of post-
infection. The risk of reactivation is greater in HIV-
infected patients (15%).8 Intracellular replication 
is initiated before responses of the immune system 
occurs in the lymph nodes and other extra pulmo-
nary sites, and thus avoids eradication by the host-
immune system.8,9
Natural division and growth of Mycobacterium 
species differs based on slowly-growing to rapidly-
growing characteristics. Slowly-growing Mycobac-
terium (SGM) require more than 7 days for visible 
growth, as opposed to rapidly-growing Mycobacte-
rium (RGM) which requires , 7 days when grown 
on Löwenstein-Jensen (L∼J) medium. However, the 
RGM may require . 1 week if grown from clini-
cal specimens.10,11 In healthy adults, tuberculosis 
 progression is generally slow. Tuberculosis infection 
shows several significant clinical manifestations in 
pulmonary and extra-pulmonary sites.12 Prolonged 
coughing, severe weigh-lost, night sweats, low-
grade fever, dyspnoea and chest pain are clinical 
symptoms indicated from pulmonary infections. The 
extra-pulmonary manifestations of M. tuberculosis 
infection include meningitis, pleuritis, pericarditis, 
synovitis, cervical lymphadenitis and infections of 
the skin, joints, bones and internal organs.8,13 In HIV-
infected tuberculosis patients, both types of clinical 
manifestation are significant due to the rapid progres-
sion of infection.
The RGM are grouped as non-tuberculous myco-
bacteria (NTM) and are opportunistic pathogens that 
can grow within 7 days in specific growth media.14,15 
To date, more than 130 species of RGM have been 
found.14 Infections due to the RGM are an emerging 
health problem in the United States.15 The most com-
mon RGM to cause human diseases are M. abscessus, 
M. chelonae, M. fortuitum, and M. massiliense and 
these have been linked with health care-associated 
pseudo-outbreaks.14,15 Chronic pulmonary disease 
and skin/soft-tissue infections are the 2 most com-
mon disorders due to these organisms.15 Clinical out-
comes in the treatment of M. abscessus infections 
are generally disappointing.15 Less common human 
pathogenic RGM species include M. phocacium, 
M. mucogenicum and M. smegmatis group (known 
as sensu stricto).14,15 The clinical and microbiologic 
features of 115 cases involving RGM isolated at the 
University of Texas from 2000–2005 were examined 
using 16S ribosomal RNA gene sequencing analysis.14 
At least 15 RGM species were included: M. abscessus 
(43 strains [37.4%]), M. fortuitum complex (33 strains 
[28.7%]), and M. mucogenicum (28 strains [24.3%]) 
were the most common, accounting for 90.4%.14 Most 
M. abscessus (32/43) were isolated from respiratory 
sources, whereas most M. mucogenicum (24/28) were 
from blood cultures.14  Antimicrobial susceptibility 
tests showed that M. abscessus was the most resistant 
species; M. mucogenicum was most susceptible.14 
From blood and catheter sources, 46 strains (40.0%) 
were isolated; 44 represented bacteremia or catheter-
related infections.14 These infections typically mani-
fested as a high fever (mean temperature, 38.9 °C), 
with a high number of RGM colonies  cultured.14 
All infections resolved with catheter removal and 
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antibiotic therapy.14 Six strains (M. abscessus and 
M. fortuitum only) were from skin, soft tissue, and 
wound infections.14 There were 59 strains from respi-
ratory sources, and 28 of these represented defini-
tive to probable infections.14 Prior lung injuries and 
 co-isolation of other pathogenic organisms were 
common.14 Overall, 78 RGM strains (67.8%) caused 
true to probable infections without direct deaths.14
The majority of RGM have been found to be 
sensitive to amikacin, gatifloxacin, moxifloxacin, 
ciprofloxacin and norfloxacin.16 Although the major-
ity of health care-associated pseudo-outbreak dis-
eases are treatable using antibiotics, the emergence 
of multidrug-resistant M. abscessus strains worsen 
the pseudo-outbreak infection scenario, due to the 
most-virulent and chemotherapy-resistant strains.16,17 
Existing diagnostic methods for MDR-TB are slower 
and take longer to perform in comparison to diag-
nostics for MTBC common infections. Second-line 
drug treatment for MDR-TB is relatively expensive 
due to the long treatment regime required to ensure 
 effectiveness and prevent recurring infections.16,17
epidemiology
Although all members of MTBC cause infection in 
humans, M. bovis, M. bovis BCG, M. Microti and 
M. pinnipedii commonly infect the warm-blooded 
animal as their primary host. It is likely that trans-
mission occurs from animal to human.18–20 Primarily, 
animal to human TB transmission cases have been 
observed in people who have worked or resided in 
a particular environment.20–23 Unlike M.  tuberculosis, 
non- tuberculous mycobacteria (NTM) are found in 
the environment, particularly moist habitats such 
as lakes, rivers and damp-soil. M. avium complex 
(MAC), M. genavense, M. kansasii, M. xenopi, 
M. simiae, M. gordonae and some RGM have been 
recovered from tap water.14,24,25 Some NTM play 
important roles in nosocomial disease and pseudo-
outbreaks and have been isolated from skin, upper 
respiratory tract, intestinal tract and genital tract of 
non-symptomatic individuals.26
Mycobacterium bovis is a slow-growing (16 to 
20 hour generation time) aerobic bacterium and is the 
causative agent of tuberculosis in cattle (known as 
bovine TB). Mycobacterium bovis can also jump the 
species barrier and cause tuberculosis in humans. The 
European badger (Meles meles) has been  identified as 
a wildlife reservoir of bovine tuberculosis and a source 
of transmission to cattle in Britain and Ireland.27 Both 
behavioral ecology and statistical ecological model-
ing have indicated the long-term persistence of the 
disease in some badger communities, and this is pos-
tulated to account for the high incidence of bovine 
tuberculosis in cattle across large tracts of England 
and Wales.27 Since few of the badgers collected in 
road traffic accidents between 1972 and 1990 had 
tuberculosis in counties such as Cheshire, where the 
disease had until shortly before that been rife in the 
cattle population, the role of badgers as reservoirs 
in spreading disease in similar counties outside the 
south-west of England has to be questioned.27
Mycobacterium africanum and M. canetti tuber-
culosis infection is mainly reported in tropical 
Africa.28,29 M. africanum can be subdivided into type I 
(M. bovis-like) and II (M. tuberculosis-like) based on 
chromosomal deletion distribution and geographic 
origin.29,30 Infected patients exhibit similar pulmo-
nary clinical features when infected with both strains. 
However, patients infected with M. africanum type II 
are more likely to present with major lung complica-
tions.31 Although the main reservoir of M. canetti is 
unknown, patients show M. tuberculosis-related pul-
monary clinical features as well as lymphadenitis in 
tuberculosis-infected children.
Global Infection Trends
From 2009 to 2012, the majority of tuberculo-
sis cases were reported from less-developed areas, 
with the highest death rates being recorded in the 
 poorest regions of Africa, India, China and  Southeast 
Asia (approximately 20 to 40 rate per 100,000 
population).13,32 The higher prevalence of MTBC 
in developing countries is known to involve several 
factors such as poverty and limited access to health-
care systems, close-contact with infected  tuberculosis 
patients, poor  nutrition, and reactivation of latent 
tuberculosis among HIV-infected individuals.1,12,33,34 
The World Health  Organization (WHO) Millennium 
Development Goal (MDG) target to halt and reverse 
the TB epidemic by 2015 has already been achieved.35 
New cases of TB have been falling for several years 
and fell at a rate of 2.2% between 2010 and 2011.35 
The TB mortality rate has decreased 41% since 1990 
and the world is on track to achieve the global target 
of a 50% reduction by 2015.35 Mortality and incidence 
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rates are also falling in all of WHO’s 6 regions and 
in most of the 22 high-burden countries that account 
for over 80% of the world’s TB cases. At the country 
level, Cambodia demonstrates what can be achieved 
in a low- income and high-burden country: new data 
show a 45% decrease in TB prevalence since 2002.35 
However, the global burden of TB remains enormous. 
In 2011, there were an estimated 8.7 million new cases 
of TB (13% co-infected with HIV) and 1.4  million 
 people died from TB, including almost 1 million deaths 
among HIV-negative individuals and 430 000 among 
people who were HIV-positive.35 Global progress also 
conceals regional variations; the African and European 
regions are not on track to halve 1990  levels of mor-
tality by 2015.35 Between 1995 and 2011, 51 million 
people were  successfully treated for TB in countries 
that had adopted the WHO strategy, saving 20 million 
lives.35 Progress in responding to multidrug-resistant 
TB (MDR-TB) remains slow. While the number of 
cases of MDR-TB notified in the 27 high MDR-TB 
burden countries is increasing and reached almost 
60 000 worldwide in 2011, this is 1 in 5 (19%) of the 
 notified TB patients estimated to have MDR-TB.35 
There has been further progress in implementing col-
laborative TB/HIV activities (first recommended by 
WHO in 2004). These saved an estimated 1.3 million 
lives between 2005 and the end of 2011.35
Overall, the reported number global mortality rates 
from tuberculosis decreased in 2011 among 22 high 
TB burden countries.35 However, the actual number 
of deaths from HIV-related tuberculosis cases may 
still be significantly higher than previously recorded, 
due to poor diagnosis and the fact that death may not 
be recorded as being due to tuberculosis. The highest 
number of HIV-related tuberculosis cases peaked in 
Africa during the 1980s and increased steadily up to 
2004, when extensive treatment and monitoring slowed 
the epidemic.36 The rise of MDR-TB cases has become 
a major concern for the WHO. There were an esti-
mated 630,000 cases of MDR-TB among the world’s 
12  million prevalent cases reported in 2011 (Table 1).35 
This surveillance data is crucial to effectively monitor-
ing the control and spread of global TB.
Diagnosis of M. tuberculosis  
from clinical specimens
The most frequent type of sample used to detect the 
presence of M. tuberculosis is respiratory  expectorate 
or sputum. Samples are taken from potential 
patients after clinical manifestations are confirmed 
by chest X-rays, except for the HIV infected and 
elderly patients that do not show typical pulmonary 
clinical features.10,11,37 Conventionally, 3 sputum 
samples collected from persistent coughing patients 
are processed to ensure a sufficient number of 
bacilli.37,38 The sample is suspended in sterile saline 
(0.85%) or bovine albumin (0.2%) and centrifuged 
($3000 × g, 15 minutes) prior to inoculation of the 
sediment.37,38
Mycobacterium tuberculosis detection from pre-
processed samples is performed by acid-fast staining 
to identify the presence of acid-fast bacillus (AFB), 
followed by culturing on solid media. Due to the 
slowly-growing character of M. tuberculosis, at least 
4 to 8 weeks are required for visible growth on solid 
media.37,38 The Centers for Disease Control and Pre-
vention (CDC) recommends that positive results from 
AFB smears must be reported after 24 hours of receipt 
of the specimen.12,38 The standard culture media used 
in many diagnostic laboratories for identification of 
M. tuberculosis isolated from sputum samples are 
L∼J, Kirchner solid/liquid media, and Middlebrook 
(7H9, 7H10 and 7H11) formulation agar and broth. 
Following confirmation of tuberculosis from stan-
dard protocols, an AFB microscopy analysis must 
be performed to ensure the prescribed treatment is 
successful.38,40
Microscopy Techniques
The most common microscopy technique used for the 
detection of mycobacteria is light microscopy com-
bined with a ZN stain smear and is rapid and cheaper 
in comparison to other methods described below. The 
sensitivity detection of ZN staining microscopy anal-
ysis can be as low as 5 × 103 AFBs/mL and detection 
proficiency may be between 22% to 80% of culture 
positive respiratory specimen.10,11 Previous studies 
have shown that using . 5 mL of a sputum sample 
increased detection sensitivity by 3-fold AFBs/mL, 
in contrast to processed/concentrated sputum sam-
ples (1 × 103:1 × 106 AFB/mL).39 Whilst the speci-
ficity of performing smears to detect mycobacteria is 
quite high, prolongation of decontamination and con-
centrating processes from sputum samples, as well 
as shortening culture incubation time, may result in 
smear-positive, but culture-negative results.
Talip
44 Infectious Diseases: Research and Treatment 2013:6
Ta
bl
e 
1.
 e
st
im
at
ed
 b
ur
de
n 
of
 d
is
ea
se
 c
au
se
d 
by
 T
B
, 2
01
1.
 N
um
be
rs
 in
 th
ou
sa
nd
s.
a
po
pu
la
tio
n
M
or
ta
lit
yb
pr
ev
al
en
ce
In
ci
de
nc
e
H
IV
-p
os
iti
ve
  
in
ci
de
nt
 T
B
 c
as
es
B
es
tc
Lo
w
H
ig
h
B
es
t
Lo
w
H
ig
h
B
es
t
Lo
w
H
ig
h
B
es
t
Lo
w
H
ig
h
A
fg
ha
ni
st
an
32
35
8
13
5.
3
23
11
0
55
19
0
61
51
73
0.
3
0.
2
0.
4
B
an
gl
ad
es
h
15
04
94
68
29
12
0
62
0
30
0
11
00
34
0
28
0
40
0
0.
6
0.
3
1
B
ra
zi
l
19
66
55
5.
6
4.
6
6.
8
91
36
17
0
83
69
97
16
13
19
C
am
bo
di
a
14
30
5
9.
1
4.
2
16
12
0
99
14
0
61
52
70
3.
1
2.
6
3.
6
C
hi
na
13
47
56
5
47
45
49
14
00
12
00
16
00
10
00
89
0
11
00
13
8.
6
17
D
R
_C
on
go
67
75
8
36
16
65
35
0
18
0
57
0
22
0
19
0
25
0
34
27
41
e
th
io
pi
a
84
73
4
15
11
20
20
0
16
0
24
0
22
0
16
0
28
0
38
28
49
In
di
ad
12
41
49
2
30
0
19
0
43
0
31
00
21
00
43
00
22
00
20
00
25
00
94
72
12
0
In
do
ne
si
a
24
23
26
65
29
12
0
68
0
31
0
12
00
45
0
38
0
54
0
15
11
20
K
en
ya
41
61
0
9.
2
4.
7
15
12
0
63
20
0
12
0
11
0
12
0
47
45
49
M
oz
am
bi
qu
e
23
93
0
11
4
22
12
0
56
20
0
13
0
91
18
0
83
58
11
0
M
ya
nm
ar
48
33
7
23
11
40
24
0
19
0
31
0
18
0
16
0
21
0
18
15
22
N
ig
er
ia
16
24
71
27
6.
1
64
28
0
71
62
0
19
0
90
33
0
50
23
86
P
ak
is
ta
n
17
67
45
59
26
11
0
62
0
28
0
11
00
41
0
34
0
49
0
1.
5
1
2.
1
P
hi
lip
pi
ne
s
94
85
2
28
25
31
46
0
40
0
52
0
26
0
21
0
31
0
1.
1
0.
6
1.
6
R
us
si
an
 F
ed
er
at
io
n
14
28
36
22
22
23
18
0
72
33
0
14
0
12
0
16
0
9.
3
7.
4
11
S
ou
th
 A
fri
ca
50
46
0
25
11
44
39
0
20
0
63
0
50
0
41
0
60
0
33
0
27
0
39
0
Th
ai
la
nd
69
51
9
9.
8
4.
2
18
11
0
51
20
0
86
71
10
0
13
10
15
U
ga
nd
a
34
50
9
5
2.
1
9
63
33
10
0
67
54
81
35
28
42
U
R
_T
an
za
ni
a
46
21
8
6.
4
3.
3
11
82
43
13
0
78
73
83
30
28
32
vi
et
na
m
88
79
2
30
12
55
29
0
13
0
50
0
18
0
14
0
22
0
14
11
18
Zi
m
ba
bw
e
12
75
4
6
2.
4
11
70
37
11
0
77
59
96
46
36
58
H
ig
h-
bu
rd
en
 C
ou
nt
rie
se
43
70
71
9
82
0
68
0
98
0
97
00
83
00
11
00
0
71
00
68
00
75
00
89
0
81
0
97
0
A
FR
85
73
82
22
0
18
0
27
0
25
00
21
00
30
00
23
00
21
00
24
00
87
0
80
0
95
0
A
M
R
94
30
19
21
18
24
33
0
25
0
42
0
26
0
24
0
28
0
37
34
40
e
M
R
60
86
28
99
61
15
0
10
00
66
0
15
00
66
0
59
0
74
0
8.
7
7.
6
9.
9
e
U
R
89
95
00
45
44
46
50
0
37
0
65
0
38
0
35
0
40
0
23
20
25
S
e
A
R
18
30
36
1
48
0
35
0
63
0
50
00
38
00
63
00
35
00
32
00
37
00
14
0
12
0
17
0
w
P
R
18
08
79
7
13
0
10
0
15
0
25
00
22
00
28
00
17
00
15
00
18
00
36
31
42
G
lo
ba
l
69
47
68
7
99
0
84
0
11
00
12
00
0
10
00
0
13
00
0
87
00
83
00
90
00
11
00
10
00
12
00
n
ot
es
: 
a N
um
be
rs
 f
or
 m
or
ta
lit
y,
 p
re
va
le
nc
e 
an
d 
in
ci
de
nc
e 
sh
ow
n 
to
 t
w
o 
si
gn
ifi
ca
nt
 fi
gu
re
s.
 T
ot
al
s 
(H
B
C
s,
 r
eg
io
na
l a
nd
 g
lo
ba
l) 
ar
e 
co
m
pu
te
d 
pr
io
r 
to
 r
ou
nd
in
g;
 b
m
or
ta
lit
y 
ex
cl
ud
es
 d
ea
th
s 
am
on
g 
H
IV
-p
os
iti
ve
 T
B
 c
as
es
. D
ea
th
s 
am
on
g 
H
IV
-p
os
iti
ve
 T
B
 c
as
es
 a
re
 c
la
ss
ifi
ed
 a
s 
H
IV
 d
ea
th
s 
ac
co
rd
in
g 
to
 IC
D
-1
0;
 c b
es
t, 
lo
w
 a
nd
 h
ig
h 
in
di
ca
te
 th
e 
po
in
t e
st
im
at
e 
an
d 
lo
w
er
 a
nd
 u
pp
er
 
bo
un
ds
 o
f t
he
 9
5%
 u
nc
er
ta
in
ty
 in
te
rv
al
; d
es
tim
at
es
 fo
r I
nd
ia
 h
av
e 
no
t y
et
 b
ee
n 
of
fic
ia
lly
 a
pp
ro
ve
d 
by
 th
e 
M
in
is
try
 o
f H
ea
lth
 a
nd
 F
am
ily
 W
el
fa
re
, G
ov
er
nm
en
t o
f I
nd
ia
, a
nd
 s
ho
ul
d 
th
er
ef
or
e 
be
 
co
ns
id
er
ed
 p
ro
vi
si
on
al
; e
A
FR
: w
H
O
 A
fri
ca
n 
R
eg
io
n,
 A
M
R
: w
H
O
 R
eg
io
n 
of
 th
e 
A
m
er
ic
as
, e
M
R
: w
H
O
 e
as
te
rn
 M
ed
ite
rr
an
ea
n 
R
eg
io
n,
 e
U
R
: w
H
O
 e
ur
op
ea
n 
R
eg
io
n,
 S
e
A
R
: w
H
O
 S
ou
th
-e
as
t 
A
si
a 
R
eg
io
n 
an
d 
W
P
R
: W
H
O
 W
es
te
rn
 P
ac
ifi
c 
R
eg
io
n.
 R
ep
ro
du
ce
d 
w
ith
 p
er
m
is
si
on
 fr
om
 W
or
ld
 H
ea
lth
 O
rg
an
iz
at
io
n 
(W
H
O
).3
5
Mycobacterium update
Infectious Diseases: Research and Treatment 2013:6 45
Fluorescent microscopy with fluorochrome stains, 
such as single auramine O or the combination of 
auramine-rhodamine B, is quicker to perform and 
more sensitive.38 The auramine O fluorescence is 
enhanced on binding to DNA or RNA as opposed to 
the carbol fuchsin dye that stains the cell membrane 
in ZN staining. Despite being more sensitive and tak-
ing less time to perform, fluorescent microscopy uses 
mercury vapor as the light source and so may pose 
a health risk to the lab operative.40.41 Furthermore, 
there is a requirement for a dark room, equipment 
and reagents are more expensive. As a result small 
laboratories may be cost-compromised. Despite 
quick results, microscopy analysis using either ZN 
or fluorochrome staining dyes may potentially give 
false-positive results due to cross contamination from 
many sources, such as the presence of Gram- positive-
like Nocardia sp.42 False-positive results may also be 
due to the handling process, suitability of stain used 
for NTM, the transfer of AFB from slides to slides 
through immersion oil and misinterpretation of results 
by untrained lab personnel.43 In addition, light and 
fluorescent microscopy is not adequately sensitive 
for the detection of MDR-TB and cannot differentiate 
between MTBC and NTM.44,45
A peptide nucleic acids (PNAs) fluorescent tech-
nique is another alternative in microscopy, which 
can be used to distinguish between M. tuberculo-
sis and NTM directly in respiratory specimens.38,46 
This technique uses a peptide-like structure to 
replace the sugar phosphate backbone and binds 
at specific sequences such as 16S rRNA. Due to 
the hydrophobicity of PNA, it can enter the myco-
bacterial cell wall and bind to intracellular nucleic 
acid sequences and is visualized using fluorescent 
microscopy.46
culture Techniques
Conventional methods for tuberculosis detection 
using AFB microscopic staining are insensitive due to 
the misinterpretation with other genus of AFB group 
 (Gordonia, Norcadia, Rhodococcus and Tsukamurella). 
Sub-culturing concentrated respiratory specimens, 
together with clinical indicators, remains the most reli-
able method of mycobacterial  identification. Culture 
on solid or broth media (selective and non- selective) 
remains the gold standard method for  detection of the 
phenotypic Mycobacterium.47,48 The option of using 
solid or liquid media depends on the routine practices 
and preferences of the laboratory; however, both must 
be optimized to ensure the rapid detection and reduc-
tion of risks for cross contamination. The common 
media used to culture mycobacterial species is L∼J or 
 Kirchner and various Middlebrook formulations (7H9, 
7H10 and 7H11).38,49 Egg-based L-J media is most 
commonly used to recover M.  tuberculosis and can 
poorly recover other species without modifications 
such as additional of glycerol (M. ulcerans) or sub-
stitution of glycerol with pyruvate (M. bovis). Visible 
colonies may be observed within 18 to 24 days.49,50 
Visible growth on an agar-based media (Middlebrook 
formulation) may be observed in 10 to 12 days. Early 
growth of microscopic colonies can be observed at 
10× and 100× magnifications due to media trans-
parency after 11 days (7H11).  Agar-based media 
can be used for drug susceptibility testing in com-
parison to egg-based media as this is due to the 
inhibition of contaminant growth. Like L∼J media, 
substitution and addition of certain chemical com-
pounds facilitates the recovery of mycobacterial 
species.48–50 Addition of 0.1% enzymatic hydro-
lysate of casein Middlebrook 7H11 improves the 
recovery of isonazid-resistant M. tuberculosis. The 
addition of antimicrobial agents enables the elimina-
tion of contaminating organisms and plays a role of 
selective media. However, the use of selective media 
should be in conjunction with either egg- or media-
based media.48–50
Immunodiagnostic Tests  
for Tuberculosis
The immuno-based tests are performed following 
clinical diagnosis. The classic serologic test for tuber-
culosis is tuberculin-serological-testing. However, this 
method is incapable of distinguishing active tubercu-
losis disease from past-sensitization of BCG, it has 
unknown predictive values and it allows cross-reac-
tion with NTM.51,52 In clinical application, serological 
tests have not been used widely due to the insensitivity 
and low antigen specificity. 2 systems of whole-blood 
IGRA determination kits, T-SPOT.TB and QuantiF-
ERON Gold In-Tube (QFNG-IT) are also available to 
use with the TST.51–53 Both systems use the principles 
of response of T-cell IFN-γ to M. tuberculosis spe-
cific antigens (ESAT-6, CFP-10 and TB 7.7) for .16 
to 24 hour incubation periods. The T-SPOT.TB assay 
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is based on an enzyme-linked immunospot assay 
 methodology that requires  approximately 250,000 
peripheral blood mononuclear cells per test well. In 
contrast, the QFNG-IT is  performed by employing 
whole blood to the M. tuberculosis antigen pre-coated 
tube which is simpler, quicker and reproducible.53 
 Studies have shown that several variables affect the 
diagnosis of pulmonary tuberculosis including age, 
country of origin, symptoms, AFB positivity and dura-
tion of exposure of patient to infection.51–54 Detection 
sensitivity is higher with IGRA testing kits (QFNG-
IT and T-SPOT.TB) in comparison with TST.55,56 
Although several comparison studies of IGRA for M. 
tuberculosis have been carried out, their clinical appli-
cation is still limited, especially among at-risk popula-
tions and children.55–57
Nucleic Acid Amplification  
(nAA) Assays
The limitations of AFB microscopy analysis and the 
length of time required for culture methods have led 
to the development of NAA assays.58–60 Polymerase 
chain reaction (PCR) provides a rapid and specific 
diagnostic technique for the simultaneous detec-
tion and identification of MTBC or NTM species 
from clinical samples.59–61 However, NAA assays 
are relatively expensive, requiring a fully equipped 
laboratory and trained personnel. Several commer-
cially-available kits based on classical PCR or iso-
thermal amplification qualitative assays have been 
developed. These include Amplified Mycobacterium 
tuberculosis direct test (AMTD), the AMPLICOR 
Mycobacterium tuberculosis Test (AMPLICOR M. 
tuberculosis), the COBAS AMPLICOR M. tubercu-
losis test and the COBAS TaqMan M. tuberculosis 
test.62,63
AMTD is the only commercial NAA assay kit 
approved by Food and Drug Administration (FDA) 
for smear-positive and smear-negative respiratory 
specimens due to the higher sensitivity and speci-
ficity compared to other NAA assays.37,59,61–63 The 
AMTB or Gen-Probe assay uses the transcriptional 
mediated amplification (TMA) and hybridiza-
tion protection methods to amplify an RNA target 
gene (16S rRNA) at constant temperature (42oC), 
in ,4 hours.59,63 There are 2 types of AMTD assays, 
Gen-Probe AMTD and AMTD2. The Gen-Probe 
AMTD assay detects MTBC rRNA in a single tube, 
contrary to AMTD2, which enables detection of all 
organisms within MTBC.61 Following clinical mani-
festations, smear-positive and smear negative respi-
ratory samples are cultured for tuberculosis infection 
confirmation and requires up to 8 weeks to obtain 
culture conversion prior to results validation.64 
Therefore, detection using the NAA assay enables 
early confirmation, especially for culture-negative 
samples. NAA testing for specimens collected from 
patients treated with anti-tuberculosis drugs within 
12 months is excluded to avoid false-positive results. 
BD ProbeTec also uses isothermal amplification.65,66 
The amplification method used is strand displace-
ment amplification, which amplifies a specific trans-
posable element of M. tuberculosis (IS6110).65–67 The 
line-probe assay involves amplification followed by 
reverse hybridization of amplicons to immobilized 
and membrane-bound probes.68 The commercial first 
line probe assay provides detection for rifampin-resis-
tant M. tuberculosis from culture and NTM including 
M. kansasii, M. xenopi, M. avium, M. chelonae, M. 
scrofulaceum, M. gordonae and M. intracellulare.68 
However, a second line-probe assay (GenoType 
MTBDRplus) was developed to detect the mutation 
of rpoB and inhA mutation (rifampin and isoniazid 
resistance) in MTBC, enabling the detection of NTM 
isolated directly from clinical specimens.69
The simultaneous detection of multiple genetic 
sequences of M. tuberculosis and mutation in drug 
resistance can be performed using oligonucleotide 
microarray technology.70,71 A DNA microarray for 
simultaneous detection of various drug resistant 
tuberculosis targeting different genetic markers (katG, 
inhA, rpoB, rpsL and gyrA) is actively being devel-
oped.40,60 The use of microarray technology may lead 
to the development of a new biomarker for detection 
of MDR- and XDR-TB. The urgent need for quali-
fied tuberculosis biomarkers enables the prediction 
of reactivation and cure and also indicates vaccine-
induced protection.73–75
The Xpert MTB/RIF is a rapid molecular test 
that can diagnose TB and rifampicin resistance 
within 100 minutes directly from sputum samples.35 
Between its endorsement by WHO in December 
2010 and the end of June 2012, 1.1 million tests 
had been purchased by 67 low- and middle-income 
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countries; South Africa (37% of purchased tests) is 
the leading adopter.35 A 41% price reduction (from 
US$ 16.86 to US$ 9.98) in August 2012 should 
accelerate uptake.35 An on-demand patient detection 
system such as the GeneX-pert system by Cepheid 
is one of the current detection assays that detects 
the rifampin-resistance. This single-tube molecular 
beacon-based real-time PCR assay targets a muta-
tion in the rifampin  resistance-determining region 
(RRDR) of the rpoB gene.72 Although this assay has 
been approved by the WHO, it is unable to detect 
isoniazid resistance.72
Discussion
Improved and affordable molecular-based detection 
technologies for MTBC, including highly sensitive, 
rapid and less-laborious techniques are needed espe-
cially in high-risk populations with poorly-resourced 
laboratories. There are critical funding gaps for TB 
care and control.35 Between 2013 and 2015, up to 
US$ 8 billion per year is needed in low- and mid-
dle-income countries, with an annual funding gap of 
up to US$ 3 billion.35 International donor funding is 
especially critical to sustain recent gains and make 
further progress in 35 low-income countries (25 in 
Africa), where donors provide more than 60% of cur-
rent funding.35
The modern concept of drug discovery utilizes 
the integrated knowledge of genomics, proteom-
ics, molecular biology and systems biology to 
identify more specific targets. The development 
of new drugs and new vaccines is also progress-
ing. New or  re-purposed TB drugs and novel TB 
regimens to treat drug-sensitive or drug resistant 
TB are advancing in clinical trials and regulatory 
review.35 11 vaccines to prevent TB are moving 
through developmental stages.35 However, to be 
significantly successful, these potential vaccine(s) 
must be made affordable and available to develop-
ing countries.
Whole-genome sequencing of bacteria has 
recently emerged as a cost-effective and  convenient 
approach for addressing many microbiological 
questions.77 In developed countries, the applica-
tion of next- generation sequencing may soon be 
sufficiently fast, accurate and cheap to be used in 
routine clinical microbiology practice, where it 
could replace many complex current techniques 
with a single, more efficient workflow.77 During 
the past 20 years, microbial detection methods 
that are genetically based, such as real-time PCR 
and peptide nucleic acid fluorescent hybridization, 
coexisted with traditional microbiological meth-
ods and were typically based on the identification 
of individual genetic targets.78 For these meth-
ods to be successful, a potential cause of infec-
tion must be suspected. More recently, multiplex 
PCR and multiplex RT-PCR were used to enable 
more broad-range  testing based on panels of sus-
pected pathogens.78 PCR-electrospray ionization 
mass spectrometry (PCR-ESI/MS) has emerged as 
a technology that is capable of identifying nearly 
all known human pathogens either from micro-
bial isolates or directly from clinical specimens.78 
Assay primers are strategically designed to target 
one or more of the broad pathogen categories: 
bacterial, mycobacterial, fungal, or viral.78 With 
broad-range amplification followed by detection of 
mixed amplicons, the method can identify genetic 
evidence of known and unknown pathogens.78 This 
unique approach supports a higher form of inquiry, 
asking the following question: What is the genetic 
evidence of known or unknown pathogens in the 
patient sample?78 This approach has advantages 
over traditional assays that commonly target the 
presence or absence of one or more pathogens 
with known genetic composition.78 However, the 
widespread application of these relatively new 
techniques in clinical laboratories will require 
significant retraining and method validation, and 
without significant financial aid will remain in 
more wealthy countries.
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